Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective

Bone Marrow Transplant. 2024 Apr;59(4):572-574. doi: 10.1038/s41409-024-02228-z. Epub 2024 Feb 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antigens, CD19
  • Costs and Cost Analysis
  • Delivery of Health Care
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Lymphoma, Non-Hodgkin*
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell
  • Antigens, CD19